• Blog
  • Neurodegenerative Drugs Market Analysis

    Neurodegenerative Drugs Market Analysis

    Neurodegenerative Drugs Market Analysis
    Report code - SR1452 Delivery - 2 Weeks
    Get Free Sample |
    Neurodegenerative Drugs Market Trends, Dynamics & Market Insights
    See more...

    Market Insights

    The Neurodegenerative Drugs Market was estimated to grow from USD 41.91 billion in 2021 to USD 67.08 billion by 2028 at a CAGR of around 6.91% during the forecast period.

    Wish to get a free sample? Register Here.

    What is neurodegenerative disease?

    Neurodegenerative disease is defined as a group of diseases that affects the neurons in the human brain. The inability of neurons to reproduce themselves results in the development of neurodegenerative diseases. Neurodegenerative diseases include multiple sclerosis, Parkinson's disease, Alzheimer's disease, spinal muscular atrophy (SMA), and others.

    Key Players

    Key players operating in the neurodegenerative drugs market are-

    • Novartis International AG (Switzerland)
    • Pfizer Inc. (US)
    • Merck Serono (Germany)
    • Biogen Inc. (US)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Benetton Group S.r.l. (Italy)
    • C.H. Boehringer Sohn AG & Ko. KG (Germany)
    • Sanofi S.A. (France)
    • GlaxoSmithKline plc (UK).

    Market Dynamics

    The growth of the neurodegenerative drugs market is primarily driven by the increasing prevalence of Alzheimer's and Parkinson's diseases. Expanding the geriatric populace across geographies is likely to drive market growth at a significant rate during the review period. In addition to this, increasing investment in research and development activities to develop new treatment methods is likely to create lucrative opportunities for the players operating in the global neurodegenerative drugs market in the coming years.

    Get the full scope of the report, Register Here.

    Segment Analysis

    By Type

    The market has been bifurcated into n-methyl-d-aspartic acid (NMDA), selective serotonin reuptake inhibitors (SSRIs), dopamine inhibitors, and others. The n-methyl-d-aspartic acid (NMDA) segment accounted for the largest market share in 2021 and is projected to register significant growth during the review period.

    Regional Analysis

    The North American market accounted for the largest market share in 2021 and is projected to grow at a robust CAGR during the review period. This can be attributed to rising healthcare expenditure and expanding geriatric populace coupled with the presence of key market players such as Pfizer Inc. (US) and Biogen Inc. (US). The market growth in Asia-Pacific is expected to be driven by the rising number of people suffering from Alzheimer's disease.

    Know which region offers the best growth opportunities, Register Here.

    Market Segmentation

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    Report – Features

    Market Segmentation

    4

    Regions Covered

    4

    Countries/Sub-Regions Covered

    14

    No. of Figures & Tables

    >150

    Company Profiles

    9

    The market is segmented into the following categories. 

    By Type

    • N-Methyl-D-Aspartic Acid (NMDA)
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Dopamine Inhibitors
    • Others

    By Disease Indication Type

    • Multiple Sclerosis
    • Parkinson’s Disease
    • Alzheimer's Disease
    • Spinal Muscular Atrophy (SMA)
    • Others

    By Distribution Channel Type

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online

    By Region

    • North America
    • Asia-Pacific
    • Europe 
    • Rest of the World

    Want to get more details about the segmentations, Click here.

    COVID-19 Impact

    The COVID-19 outbreak adversely affected the market growth of the neurodegenerative drugs industry due to the shift of medical treatment from cancer to rising coronavirus-affected patients. Patients suffering from other diseases were asked to postpone their surgery/treatment due to a rapid surge in COVID-19 cases across the globe. 

    Critical Questions Answered in the Report

    • What are the key trends in the market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the market?
    • What are the key strategies adopted by the major vendors to lead in the market?
    • What is the market share of the top vendors?

    Target Audience

    Here is the list of the group of customers that the neurodegenerative drugs market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Overview, industry life cycle analysis, supply chain analysis.
    • Environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
    • Trend and forecast analysis.
    • Segment trend and forecast.
    • Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
    • Attractive market segments and associated growth opportunities.
    • Emerging trends.
    • Strategic growth opportunities for the existing and new players.
    • Key success factors.

    Neurodegenerative Drugs Market Features

    Market Size in 2028

    USD 67.08 billion

    Market Size in 2021

    USD 41.91 billion

    Market Growth (2022-2028)

    6.91% CAGR

    Base Year of Study

    2021

    Trend Period

    2016-2020

    Forecast Period

    2022-2028

    Segments Covered

    By Type (N-Methyl-D-Aspartic Acid (NMDA), Selective Serotonin Reuptake Inhibitors (SSRIs), Dopamine Inhibitors, Others)

    By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others)

    By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)

    By Region (North America, Asia-Pacific, Europe, and the Rest of the World)

    Top Companies in 2022

    • Novartis International AG (Switzerland)
    • Pfizer Inc. (US)
    • Merck Serono (Germany)
    • Biogen Inc. (US)
    • Teva Pharmaceutical Industries Ltd. (Israel)
    • Benetton Group S.r.l. (Italy)
    • C.H. Boehringer Sohn AG & Ko. KG (Germany)
    • Sanofi S.A. (France)
    • GlaxoSmithKline plc (UK)

    Dominant Region

    The North American market accounted for the largest market share in 2021.

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s market realities and future market possibilities for the forecast period of 2022 to 2028.

    The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.

    The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. 

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. 

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Customization

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Neurodegenerative disease is defined as a group of diseases that affects the neurons in the human brain. The inability of neurons to reproduce themselves results in the development of neurodegenerative diseases. Neurodegenerative diseases include multiple sclerosis, Parkinson's disease, Alzheimer's disease, spinal muscular atrophy (SMA), and others.

    The neurodegenerative drugs market was estimated to grow from USD 41.91 billion in 2021 to USD 67.08 billion by 2028.

    Novartis International AG (Switzerland), Pfizer Inc. (US), Merck Serono (Germany), Biogen Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel), Benetton Group S.r.l. (Italy), C.H. Boehringer Sohn AG & Ko. KG (Germany), Sanofi S.A. (France), GlaxoSmithKline plc (UK).

    The neurodegenerative drugs market is expected to witness an impressive growth of 6.91% CAGR in the coming years.

    The North American market accounted for the largest market share in 2021.

    The growth of the neurodegenerative drugs market is primarily driven by the increasing prevalence of Alzheimer's and Parkinson's diseases. Expanding the geriatric populace across geographies is likely to drive market growth at a significant rate during the review period. In addition to this, increasing investment in research and development activities to develop new treatment methods is likely to create lucrative opportunities for the players operating in the global neurodegenerative drugs market in the coming years.

    The n-methyl-d-aspartic acid (NMDA) segment accounted for the largest market share in 2021.

    By Type (N-Methyl-D-Aspartic Acid (NMDA), Selective Serotonin Reuptake Inhibitors (SSRIs), Dopamine Inhibitors, Other), Disease Indication (Multiple Sclerosis, Parkinsons Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), and Region- (North America, Europe, Asia-Pacific, and Rest of the World).